Option chain shows key data for Indaptus Therapeutics's stock options at various strike prices and expiration dates. Traders use this information to analyze potential trades and assess market sentiment for Indaptus Therapeutics.

Indaptus Therapeutics (NASDAQ:INDP) Stock, Option Chain

Indaptus Therapeutics

Indaptus Therapeutics Inc is a pre-clinical biotechnology company engaged in developing a novel and patented systemically-administered anti-cancer and anti-viral immunotherapy. It has developed a proprietary platform that exploits bacteria's natural ability to activate both innate and adaptive cellular immune pathways. The company's pre-clinical candidate Decoy20, has the ability to elicit single-agent activity and durable anti-tumor responses in the combination setting against colorectal, hepatocellular, pancreatic carcinoma, and non-Hodgkin's lymphoma models.

News

Penny Stocks

Small Cap

Intraday Update

Markets

Movers

Trading Ideas

ADIL

AGFY

AMRN

ARRY

AUMN

BBWI

BCAN

BEDU

BFLY

Bakkt Holdings, Inc. Class A Common Stock

BKKT

BLUE

CMPS

COMM

CRML

CSTL

CTKB

DAVA

DUOL

ENVB

ESTA

FIGS

GRFS

GYRE

HAYW

IHRT

INDP

INSG

IONQ

IRWD

LPSN

MGNI

MIST

MRSN

NARI

NTES

NWTN

OCEA

OKTA

ORIC

PSTG

PZZA

QURE

RNLX

RVNC

SCTL

SDGR

SHLS

SIDU

SNOW

STER

STKL

SWIM

TASK

VERX

VLCN

XMTR

Shares of  Butterfly Network, Inc.  (NASDAQ: BFLY) fell sharply during Thursday’s session after the company reported mixed fourth-quarter financial results.

Why Butterfly Network Shares Are Trading Lower By 22%? Here Are Other Stocks Moving In Thursday&#39;s Mid-Day Session

Pre-Market Outlook

Envoy Medical, Inc. - Class A Common Stock

COCH

ESGL

VYGR

Shares of  Okta, Inc. (NASDAQ: OKTA) shares rose sharply in today’s pre-market trading after the company reported better-than-expected fourth-quarter financial results and 

Why Okta Shares Are Trading Higher By Around 24%; Here Are 20 Stocks Moving Premarket

ACXP

AFIB

AIRE

AMWL

ASTR

BANL

BEST

BGNE

BHIL

CAUD

Cardio Diagnostics Holdings Inc. - Common stock

CDIO

CLDX

CNFR

CRBU

CREV

CTNT

DBGI

DISH

DOGZ

FRPT

GDEV

Hollsys Automation Technologies INTERNATIONAL

HOLI

KXIN

LICY

LIFW

MLTX

NSSC

PRFX

PRME

PROC

RYAAY

SATS

TGLS

VERB

WHLR

Gainers


	Carbon Revolution Public Limited  (NASDAQ: CREV) shares jumped 396.2% to $145.49 after gaining 100% on Friday. The company’s stock began trading on Friday following merger with Twin Ridge Capital Acquisition Corp.


Why Bluegreen Vacations Shares Are Trading Higher By Around 105%? Here Are Other Stocks Moving In Monday&#39;s Mid-Day Session

Indaptus Therapeutics, Inc. - Common Stock

Indaptus Therapeutics Inc

The earnings results for Blue Bird (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/BLBD#NASDAQ">BLBD</a>) for Q4 were made public on Monday, November 25, 2024 at 04:00 PM.
Here's a comprehensive overview of the announcement.
<h3>Earnings</h3>
Blue Bird missed estimated earnings by -16.0%, reporting an EPS of $0.77 versus an estimate of $0.92.
Revenue was up $47.25 million from the same period last year.
<h3>Previous Earnings Records</h3>
The company beat on EPS by $0.4 in the last quarter, resulting in a 0.0% increase share price change the following day.
Here's a look at Blue Bird's past performance:

<table>
<thead>
<tr>
<th>Quarter</th>
<th>Q3 2024</th>
<th>Q2 2024</th>
<th>Q1 2024</th>
<th>Q4 2023</th>
</tr>
</thead>
<tbody>
<tr>
<td>EPS Estimate</td>
<td>0.51</td>
<td>0.48</td>
<td>0.37</td>
<td>0.48</td>
</tr>
<tr>
<td>EPS Actual</td>
<td>0.91</td>
<td>0.89</td>
<td>0.91</td>
<td>0.66</td>
</tr>
<tr>
<td>Revenue Estimate</td>
<td>328.60M</td>
<td>298.41M</td>
<td>275.13M</td>
<td>290.11M</td>
</tr>
<tr>
<td>Revenue Actual</td>
<td>333.37M</td>
<td>345.92M</td>
<td>317.66M</td>
<td>302.96M</td>
</tr>
</tbody>
</table>

To track all earnings releases for Blue Bird <a href="https://www.benzinga.com/quote/BLBD/earnings">visit their earnings calendar here.</a> 
This article was generated by Benzinga's automated content engine and reviewed by an editor.

Earnings

BLBD

Blue Bird: Q4 Earnings Insights

The Q4 earnings report for Woodward (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/WWD#NASDAQ">WWD</a>) was released on Monday, November 25, 2024 at 04:00 PM.
Here's what investors need to know about the latest announcement.
<h3>Earnings</h3>
Woodward beat estimated earnings by 13.0%, reporting an EPS of $1.41 versus an estimate of $1.25.
Revenue was up $77.42 million from the same period last year.
<h3>Historical Earnings Summary</h3>
The company beat on EPS by $0.12 in the last quarter, resulting in a 17.0% drop share price change the following day.
Here's a look at Woodward's past performance:

<table>
<thead>
<tr>
<th>Quarter</th>
<th>Q3 2024</th>
<th>Q2 2024</th>
<th>Q1 2024</th>
<th>Q4 2023</th>
</tr>
</thead>
<tbody>
<tr>
<td>EPS Estimate</td>
<td>1.51</td>
<td>1.32</td>
<td>1.10</td>
<td>1.31</td>
</tr>
<tr>
<td>EPS Actual</td>
<td>1.63</td>
<td>1.62</td>
<td>1.45</td>
<td>0.84</td>
</tr>
<tr>
<td>Revenue Estimate</td>
<td>853.82M</td>
<td>807.00M</td>
<td>748.29M</td>
<td>765.35M</td>
</tr>
<tr>
<td>Revenue Actual</td>
<td>847.69M</td>
<td>835.34M</td>
<td>786.73M</td>
<td>777.07M</td>
</tr>
</tbody>
</table>

New investors should note that it is sometimes not an earnings beat or miss that most affects the price of a stock, but the guidance (or forecast).
<h3>Guidance</h3>
Woodward management provided guidance for FY 2025, expecting earnings between $5.75 and $6.25 per share.
To track all earnings releases for Woodward <a href="https://www.benzinga.com/quote/WWD/earnings">visit their earnings calendar here.</a> 
This article was generated by Benzinga's automated content engine and reviewed by an editor.

Woodward Earnings Review: Q4 Summary

Enanta Pharma (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/ENTA#NASDAQ">ENTA</a>) announced its Q4 earnings on Monday, November 25, 2024 at 04:01 PM.
Here's a breakdown of the earnings report.
<h3>Earnings</h3>
Enanta Pharma beat estimated earnings by 4.0%, reporting an EPS of $-1.36 versus an estimate of $-1.41.
Revenue was down $4.33 million from the same period last year.
<h3>Performance in Previous Earnings</h3>
During the previous quarter, the company beat on EPS by $0.38, leading to a 1.0% increase share price change the next day.
Here's a look at Enanta Pharma's past performance:

<table>
<thead>
<tr>
<th>Quarter</th>
<th>Q3 2024</th>
<th>Q2 2024</th>
<th>Q1 2024</th>
<th>Q4 2023</th>
</tr>
</thead>
<tbody>
<tr>
<td>EPS Estimate</td>
<td>-1.45</td>
<td>-1.33</td>
<td>-1.19</td>
<td>-2</td>
</tr>
<tr>
<td>EPS Actual</td>
<td>-1.07</td>
<td>-1.47</td>
<td>-1.58</td>
<td>-1.33</td>
</tr>
<tr>
<td>Revenue Estimate</td>
<td>17.18M</td>
<td>16.52M</td>
<td>21.28M</td>
<td>17.50M</td>
</tr>
<tr>
<td>Revenue Actual</td>
<td>17.97M</td>
<td>17.05M</td>
<td>18.00M</td>
<td>18.93M</td>
</tr>
</tbody>
</table>

To track all earnings releases for Enanta Pharma <a href="https://www.benzinga.com/quote/ENTA/earnings">visit their earnings calendar here.</a> 
This article was generated by Benzinga's automated content engine and reviewed by an editor.

ENTA

Earnings Breakdown: Enanta Pharma Q4

As of September 30, 2024, Alector has $457.2 million in cash, cash equivalents, and investments, which the company continues to expect will provide runway through 2026. Alector plans to provide guidance for 2025 during its fourth-quarter and full-year earnings conference call.

ALEC

Alector Expects Cash & Equivalents To Provide Runway Through 2026

WIIM

Agilent Technologies shares are trading lower after the company provided Q1 and FY25 adjusted EPS and revenue guidance below analyst expectations.

CENT

CENTA

Central Garden & Pet shares are trading lower after the company reported Q4 sales that missed analyst estimates, despite better-than-expected adjusted EPS.

The term "metaverse" was one of the top trends in 2021 with companies and cryptocurrencies related to the term seeing soaring valuations. While interest in the metaverse has fallen off in recent years, two cryptocurrencies with ties to the metaverse were among the <a href="https://www.benzinga.com/money/top-metaverse-coins">top gainers of the past week.</a>
What Happened: The Sandbox (CRYPTO: <a class="ticker" href="https://www.benzinga.com/quote/sand/usd">SAND</a>) and Decentraland (CRYPTO: <a class="ticker" href="https://www.benzinga.com/quote/mana/usd">MANA</a>) cryptocurrencies are among the biggest movers of the last week, gaining 107% and 57%, respectively, over the last seven days, which comes as interest in the metaverse <a href="https://www.benzinga.com/news/events/24/11/42172802/nfts-metaverse-derided-rightly-but-experts-see-bright-future-ahead" target="_blank" rel="noopener">could be growing once again.</a>
The two coins are connected to virtual worlds and were high performers in 2021 and 2022 as interest in virtual land and metaverse-related companies and cryptocurrencies soared.
While the prices of the coins are down sharply from all-time highs set in November 2021, the recent gains have the coins hitting new levels not seen in some time.
The Sandbox coin is up 27% over the last day to $0.7294, making it one of the top gainers in the last 24 hours. The coin has traded between $0.2098 and $0.8493 over the last year, with the yearly high recently hit in the past week. The all-time high for the coin is $8.44, set on Nov. 25, 2021.
The Decentraland coin is up 11% over the last day to $0.6532, making it one of the top gainers in the last 24 hours. The coin has traded between $0.2181 and $0.8185 over the last year. Over the past week, it hit new monthly highs of $0.7731. The all-time high for the coin is $5.90, set on Nov. 25, 2021.
Investors who bought the metaverse-related coins in 2021 could have generated a nice profit throughout the year and into 2022. Here's a look at their stake if they held.
Read Also: <a href="https://www.benzinga.com/markets/cryptocurrency/24/11/41908812/if-you-invested-100-in-dogecoin-when-the-meme-coin-launched-heres-how-much-youd-have-today">If You Invested $100 In Dogecoin When The Meme Coin Launched, Here&#8217;s How Much You&#8217;d Have Today</a>
Investing $1,000 in SAND, MANA: The Sandbox coin&nbsp;<a href="https://coinmarketcap.com/currencies/the-sandbox/" target="_blank" rel="noreferrer noopener">traded&nbsp;</a>at a high of $0.0379 on Jan. 1, 2021. A $1,000 investment in SAND on the first day of the year could have bought 26,385.22 SAND coins.
The $1,000 investment would be worth $19,245.38 today based on a current price of $0.7294, up 1,824.5% since the start of 2021.
The Decentraland coin&nbsp;<a href="https://coinmarketcap.com/currencies/decentraland/" target="_blank" rel="noreferrer noopener">traded&nbsp;</a>at a high of $0.0839 on Jan. 1, 2021. A $1,000 investment in MANA on the first day of the year could have bought 11,918.95 MANA coins.
The $1,000 investment would be worth $7,785.46 today based on a current price of $0.6532, up 678.5% since the start of 2021.
What's Next: The metaverse was a big topic in 2021 with the launch of virtual land from several companies, the launch of the Roundhill Ball Metaverse ETF and <a href="https://www.benzinga.com/general/education/24/10/41163360/if-you-invested-1-000-in-facebook-stock-when-mark-zuckerberg-changed-name-to-meta-heres-how-muc">the announced rebrand</a> of Facebook to Meta Platforms.
Tesla CEO Elon Musk <a href="https://www.benzinga.com/markets/cryptocurrency/21/12/24718726/is-the-metaverse-a-marketing-buzzword-or-multitrillion-dollar-opportunity-elon-musk-cathie">called the metaverse</a> a "marketing buzzword" previously.
Ark Invest CEO Cathie Wood took the other side and said the metaverse was in the early stages of development at the time.
"It's a big idea that will probably infiltrate – just like technology is, anyway – every sector in ways that we cannot even imagine right now," Wood said.
She said the metaverse could be a multitrillion-dollar opportunity, a stark contrast from Musk saying the metaverse is a marketing buzzword.
Fast-forward to today, and skepticism around the metaverse has grown, with some use cases losing their luster and excitement waning in recent years. Yet, metaverse and gaming tokens have recently surged as top crypto gainers, sparking renewed investor interest in the sector&#8217;s potential revival.
Read Next: 
<ul>
<li><a href="https://www.benzinga.com/24/11/42146874/if-you-invested-1000-in-solana-when-sam-bankman-fried-was-arrested-heres-how-much-youd-have-today">If You Invested $1,000 In Solana When Sam Bankman-Fried Was Arrested, Here&#8217;s How Much You&#8217;d Have Today</a></li>
</ul>
This article was previously published by Benzinga and has been updated.
Photo: Koshiro K/Shutterstock.com

Coverage of Bitcoin, Etherum, Ripple and all the latest digital currencies.

Cryptocurrency

$MANA

$SAND

If You Invested $1,000 In The Sandbox And Decentraland Coins On Jan. 1, 2021, Here's How Much You'd Have Now

Alector Says It Is Reducing Its Workforce By Approximately 17%, Stopping Long-term Extension Study Based Upon AL002 INVOKE-2 Phase 2 Trial Results

Zoom shares are trading lower following Q3 earnings.

Alector shares are trading lower after the company announced that the INVOKE-2 Phase 2 clinical trial evaluating the safety and efficacy of AL002 in individuals with early Alzheimer's disease failed to meet its primary endpoint.

Pennant Park Investment (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/PNNT#NYSE">PNNT</a>) reported quarterly earnings of $0.75 per share which beat the analyst consensus estimate of $0.72 by 4.17 percent.

Earnings Beats

PNNT

Pennant Park Investment FY 2024 GAAP EPS $0.75 Beats $0.72 Estimate

Stock Repurchase Authorization: In November 2024, Zoom's Board of Directors authorized the repurchase of an additional $1.2 billion of Zoom's outstanding Class A common stock. This authorization is in addition to the amount remaining under the prior authorization for the share repurchase program, for a total of approximately $2.0 billion remaining to be repurchased.
Repurchases of Zoom's Class A common stock may be effected, from time to time, either on the open market (including pre-set trading plans), in privately negotiated transactions, and other transactions in accordance with applicable securities laws.
The timing and the amount of any repurchased Class A common stock will be determined by Zoom's management based on its evaluation of market conditions and other factors. The repurchase program will be funded using Zoom's working capital. Any repurchased shares of Class A common stock will be retired. The repurchase program does not obligate Zoom to acquire any particular amount of Class A common stock, and the repurchase program may be suspended or discontinued at any time at Zoom's discretion.

Buybacks

In November 2024, Zoom's Board Of Directors Authorized The Repurchase Of An Additional $1.2B Of Outstanding Class A Common Stock; Authorization Is In Addition To The Amount Remaining Under The Prior Authorization For The Share Repurchase Program, For A Total Of ~$2B Remaining To Be Repurchased

Alector Reports Results From AL002 INVOKE-2 Phase 2 Trial In Individuals With Early Alzheimer's Disease; Says AL002 Failed To Meet Primary Endpoint

Financial Outlook:&nbsp;Zoom is providing the following guidance for its fourth quarter of fiscal year 2025 and its full fiscal year 2025.
<ul>
<li>Fourth Quarter Fiscal Year 2025: Total revenue is expected to be between $1.175 billion and $1.180 billion and revenue in constant currency is expected to be between $1.174 billion and $1.179 billion. Non-GAAP income from operations is expected to be between $443.0 million and $448.0 million. Non-GAAP diluted EPS is expected to be between $1.29 and $1.30 with approximately 315 million weighted average shares outstanding.</li>
<li>Full Fiscal Year 2025: Total revenue is expected to be between $4.656 billion and $4.661 billion and revenue in constant currency is expected to be between $4.661 billion and $4.666 billion. Full fiscal year non-GAAP income from operations is expected to be between $1.813 billion and $1.818 billion. Full fiscal year non-GAAP diluted EPS is expected to be between $5.41 and $5.43 with approximately 315 million weighted average shares outstanding. Full fiscal year free cash flow is expected to be between $1.580 billion and $1.620 billion.</li>
</ul>
The EPS and share count figures do not include the impact from the share repurchase authorization discussed below.
Additional information on Zoom's reported results, including a reconciliation of the non-GAAP results to their most comparable GAAP measures, is included in the financial tables below. A reconciliation of non-GAAP guidance measures to corresponding GAAP measures is not available on a forward-looking basis without unreasonable effort due to the uncertainty of expenses that may be incurred in the future, although it is important to note that these factors could be material to Zoom's results computed in accordance with GAAP.
A supplemental financial presentation and other information can be accessed through Zoom's investor relations website at investors.zoom.us.

Guidance

Zoom Video Communications Sees Q4 EPS $1.29-$1.30 Vs $1.28 Est.; Revenue $1.175B-$1.18B Vs $1.17B Est.; FY25 EPS $5.41-$5.43 Vs $5.35 Est.; Revenue $4.656B-$4.661B Vs $4.64B Est.

Earnings Misses

Enanta Pharmaceuticals Sees Q4 2024 Revenue $14.6M Vs $17.9M Estimate; Sees Adj. EPS $-1.36 Vs $-1.16

Agilent Technologies Sees Q1 Adj. EPS $1.25-$1.28 Vs $1.37 Est.; Revenue $1.65B-$1.68B Vs $1.697B Est.

The Company expects to grant the underwriters a 30-day option to purchase up to 2.70 million additional shares of its common stock.
The Company intends to use the net proceeds of this offering together with cash on hand, including from recent sales under the Company's "at the market" offering program, to repay the $478.0 million mortgage loan with a fixed effective interest rate of approximately 9.0% and which is secured by its Washington Square property.

Offerings

Macerich Commences Public Offering Of 18M Shares Of Common Stock

PFLT

PennantPark Floating Rate Capital Ltd. Q4 Core NII Per Share $0.32

CLRO

ClearOne Engages ARC Group To Explore Strategic Alternatives Including Merger, Sale, Or Spin-Off To Maximize Shareholder Value, With Larry Hendricks Declining Re-Election To Board In 2024

Agilent Technologies Sees FY25 Adj. EPS $5.54-$5.61 Vs $5.66B Est.; Revenue $6.79B-$6.87B Vs $6.829B Est.

Indaptus Therapeutics files to sell 1.64M shares of common stock for holders

Indaptus Therapeutics (INDP) announced a clinical supply agreement with BeiGene (BGNE). Building on Indaptus' preclinical observation that Decoy20,...

Indaptus Therapeutics announces clinical supply agreement with BeiGene

Indaptus Therapeutics (INDP – Research Report), the Healthcare sector company, was revisited by a Wall Street analyst yesterday. Analyst Jason McCa...

Optimism Surrounds Indaptus Therapeutics' Decoy20 Amid Strategic Partnerships and Promising Preclinical Data

Indaptus Therapeutics (INDP) announced that Dr. Michael Newman, Founder and Chief Scientific Officer, has published his research in the peer-review...

Indaptus Therapeutics publishes research in Frontiers in Immunology

Jeffrey Meckler, Indaptus Therapeutics (INDP)' Chief Executive Officer, commented, "The recent announcement highlighting our clinical supply agreem...

Indaptus Therapeutics reports Q3 EPS (32c) vs. (47c) last year

As of September 30, 2024, the Company had cash and cash equivalents of approximately $7.4 million. As of December 31, 2023, the Company had cash an...

Indaptus Therapeutics sees cash runway into 1Q25

Indaptus Therapeutics GAAP EPS of -$0.32

Maxim analyst Jason McCarthy lowered the firm's price target on Indaptus Therapeutics (INDP) to $5 from $8 but keeps a Buy rating on the shares. Th...

Indaptus Therapeutics price target lowered to $5 from $8 at Maxim

Indaptus Therapeutics (INDP) has entered into securities purchase agreements with investors, including an officer of Indaptus, for the issuance and...

Indaptus to sell 1.82M shares at $1.175 in registered direct offering

Indaptus Therapeutics announces $2.135M registered direct offering

Press Releases

Indaptus Therapeutics Reports Encouraging New Safety Data for Decoy20 Clinical Program; Company Expands Enrollment of Patients on Weekly Dosing at Two Different Doses

Indaptus Therapeutics to Participate in a Fireside Chat at the 2024 Maxim Healthcare Virtual Summit

Indaptus Therapeutics Founder and Chief Scientific Officer to Speak on Lumanity Webinar about the Future of Innate Immunity in Cancer Immunotherapy

Health Care

Indaptus Therapeutics Initiates Unrestricted Enrollment of Patients on Decoy20 Weekly Dosing Based on Encouraging Safety Data

Indaptus Therapeutics Announces Clinical Supply Agreement with BeiGene to Evaluate Novel Cancer Treatment Combinations

Indaptus Therapeutics to Present at Two Upcoming Investor Conferences

Indaptus Therapeutics Presents Encouraging Interim Safety Data from Phase 1 Clinical Trial of Decoy20 at the Society for Immunotherapy of Cancer (SITC) 2024 Annual Meeting

Indaptus Therapeutics' Pioneering Research on Novel Immunotherapy Approach Published in Peer-Reviewed Frontiers in Immunology

Indaptus Therapeutics Reports Third Quarter 2024 Financial Results and Provides Corporate Update

Financing

Indaptus Therapeutics, Inc. Announces $2.135 Million Registered Direct Offering and Concurrent Private Placement

Comments

Indaptus Therapeutics

Indaptus Therapeutics (INDP) Options

No option chain data available. Please try again later

Popular Channels

Tools & Features

Partners & Contributors

About Benzinga